Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection

AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and bo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Hepatol
Autors principals: Sherman, Kenneth E, Kang, Minhee, Sterling, Richard, Umbleja, Triin, Marks, Kristen, Kiser, Jennifer J, Alston-Smith, Beverly, Greaves, Wayne, Butt, Adeel A, the ACTG 5294 BIRTH Study Team
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2017
Matèries:
Clinical Trials Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5295161/
https://ncbi.nlm.nih.gov/pubmed/28217259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i4.217
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars